Pharmacoeconomic simulation of delayed results of the treatment of type 2 diabetes mellitus with modern insulin analogsin comparison with oral hypoglycemic agents

Aim. To carry out cost-effectiveness analysis of treatment options for type 2 diabetes using different groups of medicines, to prognosticate late diabeticcomplications and the cost of their management. Materials and methods. A total of 3678 DM2 patients (with mean HbAc1 level 9.3%) were examined i...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Ivan Ivanovich Dedov, Marina Vladimirovna Shestakova, Yury Ivanovich Suntsov, Roza Imailovna Yagudina, Ivan Sergeevich Krysanov, Andrey Yur'evich Kulikov, Evgenia Evgen'evna Arinina
Formato: article
Lenguaje:EN
RU
Publicado: Endocrinology Research Centre 2010
Materias:
Acceso en línea:https://doaj.org/article/6244d694f989443796f5619c483ff780
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:6244d694f989443796f5619c483ff780
record_format dspace
spelling oai:doaj.org-article:6244d694f989443796f5619c483ff7802021-11-14T09:00:14ZPharmacoeconomic simulation of delayed results of the treatment of type 2 diabetes mellitus with modern insulin analogsin comparison with oral hypoglycemic agents2072-03512072-037810.14341/2072-0351-6024https://doaj.org/article/6244d694f989443796f5619c483ff7802010-03-01T00:00:00Zhttps://www.dia-endojournals.ru/jour/article/view/6024https://doaj.org/toc/2072-0351https://doaj.org/toc/2072-0378Aim. To carry out cost-effectiveness analysis of treatment options for type 2 diabetes using different groups of medicines, to prognosticate late diabeticcomplications and the cost of their management. Materials and methods. A total of 3678 DM2 patients (with mean HbAc1 level 9.3%) were examined in 23 regionsin the framework of the Diabetesmellitus subprogram of the Federal target program "Prevention and control of socially significant diseases". Two hypothetical therapeutic modalitieswere considered: treatment with NovoMix 30 and oral hypoglycemic (OHG) agents. The CORE model was used to analyse anticipated expendituresand DM outcomes. Results. Simulation revealed a greater decrease of HbA1c levels (-1.7%), reduction of total cholesterol, LDL, systolic AP (-4.1%) and risk of cardiovasculardiseases coupled to increase of HDL in patients treated with NovoMix 30. Maximum life expectancy was 17.2 yr compared with 16.5 yrin the OHG group and overall cost of the treatment 1,650,725 and 1,586,234 rubles respectively. Savings for the treatment of diabetes using NovoMix30 amounted to 19,832 rubles per patients due to reduced indirect expenditures including management of renal, cardiac, ophthalmologic , and cerebrovascularcomplications. Conclusion. Simulation of late results of DM2 treatment demonstrated enhanced pharmacoeconomic efficiency of modern insulin analogs comparedwith OHG agents.Ivan Ivanovich DedovMarina Vladimirovna ShestakovaYury Ivanovich SuntsovRoza Imailovna YagudinaIvan Sergeevich KrysanovAndrey Yur'evich KulikovEvgenia Evgen'evna ArininaEndocrinology Research Centrearticlesimulationpharmacoeconomiccostinsulin analogsoral agentsNutritional diseases. Deficiency diseasesRC620-627ENRUСахарный диабет, Vol 13, Iss 1, Pp 101-110 (2010)
institution DOAJ
collection DOAJ
language EN
RU
topic simulation
pharmacoeconomic
cost
insulin analogs
oral agents
Nutritional diseases. Deficiency diseases
RC620-627
spellingShingle simulation
pharmacoeconomic
cost
insulin analogs
oral agents
Nutritional diseases. Deficiency diseases
RC620-627
Ivan Ivanovich Dedov
Marina Vladimirovna Shestakova
Yury Ivanovich Suntsov
Roza Imailovna Yagudina
Ivan Sergeevich Krysanov
Andrey Yur'evich Kulikov
Evgenia Evgen'evna Arinina
Pharmacoeconomic simulation of delayed results of the treatment of type 2 diabetes mellitus with modern insulin analogsin comparison with oral hypoglycemic agents
description Aim. To carry out cost-effectiveness analysis of treatment options for type 2 diabetes using different groups of medicines, to prognosticate late diabeticcomplications and the cost of their management. Materials and methods. A total of 3678 DM2 patients (with mean HbAc1 level 9.3%) were examined in 23 regionsin the framework of the Diabetesmellitus subprogram of the Federal target program "Prevention and control of socially significant diseases". Two hypothetical therapeutic modalitieswere considered: treatment with NovoMix 30 and oral hypoglycemic (OHG) agents. The CORE model was used to analyse anticipated expendituresand DM outcomes. Results. Simulation revealed a greater decrease of HbA1c levels (-1.7%), reduction of total cholesterol, LDL, systolic AP (-4.1%) and risk of cardiovasculardiseases coupled to increase of HDL in patients treated with NovoMix 30. Maximum life expectancy was 17.2 yr compared with 16.5 yrin the OHG group and overall cost of the treatment 1,650,725 and 1,586,234 rubles respectively. Savings for the treatment of diabetes using NovoMix30 amounted to 19,832 rubles per patients due to reduced indirect expenditures including management of renal, cardiac, ophthalmologic , and cerebrovascularcomplications. Conclusion. Simulation of late results of DM2 treatment demonstrated enhanced pharmacoeconomic efficiency of modern insulin analogs comparedwith OHG agents.
format article
author Ivan Ivanovich Dedov
Marina Vladimirovna Shestakova
Yury Ivanovich Suntsov
Roza Imailovna Yagudina
Ivan Sergeevich Krysanov
Andrey Yur'evich Kulikov
Evgenia Evgen'evna Arinina
author_facet Ivan Ivanovich Dedov
Marina Vladimirovna Shestakova
Yury Ivanovich Suntsov
Roza Imailovna Yagudina
Ivan Sergeevich Krysanov
Andrey Yur'evich Kulikov
Evgenia Evgen'evna Arinina
author_sort Ivan Ivanovich Dedov
title Pharmacoeconomic simulation of delayed results of the treatment of type 2 diabetes mellitus with modern insulin analogsin comparison with oral hypoglycemic agents
title_short Pharmacoeconomic simulation of delayed results of the treatment of type 2 diabetes mellitus with modern insulin analogsin comparison with oral hypoglycemic agents
title_full Pharmacoeconomic simulation of delayed results of the treatment of type 2 diabetes mellitus with modern insulin analogsin comparison with oral hypoglycemic agents
title_fullStr Pharmacoeconomic simulation of delayed results of the treatment of type 2 diabetes mellitus with modern insulin analogsin comparison with oral hypoglycemic agents
title_full_unstemmed Pharmacoeconomic simulation of delayed results of the treatment of type 2 diabetes mellitus with modern insulin analogsin comparison with oral hypoglycemic agents
title_sort pharmacoeconomic simulation of delayed results of the treatment of type 2 diabetes mellitus with modern insulin analogsin comparison with oral hypoglycemic agents
publisher Endocrinology Research Centre
publishDate 2010
url https://doaj.org/article/6244d694f989443796f5619c483ff780
work_keys_str_mv AT ivanivanovichdedov pharmacoeconomicsimulationofdelayedresultsofthetreatmentoftype2diabetesmellituswithmoderninsulinanalogsincomparisonwithoralhypoglycemicagents
AT marinavladimirovnashestakova pharmacoeconomicsimulationofdelayedresultsofthetreatmentoftype2diabetesmellituswithmoderninsulinanalogsincomparisonwithoralhypoglycemicagents
AT yuryivanovichsuntsov pharmacoeconomicsimulationofdelayedresultsofthetreatmentoftype2diabetesmellituswithmoderninsulinanalogsincomparisonwithoralhypoglycemicagents
AT rozaimailovnayagudina pharmacoeconomicsimulationofdelayedresultsofthetreatmentoftype2diabetesmellituswithmoderninsulinanalogsincomparisonwithoralhypoglycemicagents
AT ivansergeevichkrysanov pharmacoeconomicsimulationofdelayedresultsofthetreatmentoftype2diabetesmellituswithmoderninsulinanalogsincomparisonwithoralhypoglycemicagents
AT andreyyurevichkulikov pharmacoeconomicsimulationofdelayedresultsofthetreatmentoftype2diabetesmellituswithmoderninsulinanalogsincomparisonwithoralhypoglycemicagents
AT evgeniaevgenevnaarinina pharmacoeconomicsimulationofdelayedresultsofthetreatmentoftype2diabetesmellituswithmoderninsulinanalogsincomparisonwithoralhypoglycemicagents
_version_ 1718429654485827584